Bio-Rad Laboratories (NYSE:BIO) has recently been downgraded to a 'Hold' rating, following numerous missed earnings estimates. The company has experienced a Q3 net loss which casts a shadow on the stock's recovery narrative. Amidst these developments, BIO shares have crossed below the 200 DMA, causing stock values to fall by over 11% on Feb 13. Despite this, the Q4 2025 earning calls were maintained, regardless of the earnings falling below expectations. There has been a significant slump in the company's stock value even with the formulation of new margin goals. This underperformance has prompted the consideration of the company's valuation after a prolonged share price weakness. The surprising tumble in share values has caused analysts to term the stock as oversold. There have been mixed Q4 2025 financial results and predictions of future performance remain uncertain. Nonetheless, the overall adjustments to earnings and the fall in revenue have resulted in shares dropping after hours. Recent validation of the company's EZ-Boost Listeria Kits has sparked consideration in altering the current investment case. Lowered price targets and steady growth amid segment divergence and strategic shifts have been observed. The view that the company could be undervalued following the stock's significant drop and low debt remains in consideration.
Bio-Rad Laboratories Stocks News Analytics from Mon, 11 Nov 2024 08:00:00 GMT to Sat, 14 Feb 2026 14:14:49 GMT -
Rating -6
- Innovation -3
- Information 2
- Rumor 3
